Division of Plastic & Reconstructive Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
J Craniofac Surg. 2021 Sep 1;32(6):2168-2171. doi: 10.1097/SCS.0000000000007557.
Although it appears to be a simple, easy, and financially attractive therapeutic modality, skin rejuvenation mesotherapy is a controversial cosmetic procedure and proof of its efficacy is still lacking. The authors have published a review about this therapeutic modality more than a decade ago. Few clinical studies evaluating its efficacy and safety were available then without any conclusive scientific evidence about its efficacy; nevertheless, mesotherapy has continued to be performed at a relatively high financial cost to patients by many nonmedical and medical professionals for antiaging purposes. The authors have published a review about this therapeutic modality more than a decade ago. The current review is an update aimed at identifying any evidence about the scientific validity and efficacy of this approach that has emerged since then. No clinical valuable new data and new information has been identified. As by American Society of Plastic Surgeons (ASPS) policy statement updated and approved in 2019, mesotherapy for skin rejuvenation is currently not Food and Drug Administration approved. Until more conclusive data is available, skin rejuvenation mesotherapy cannot be recommended for routine skin rejuvenation clinical application.
虽然皮肤年轻化中胚层疗法看起来简单、容易且具有经济吸引力,但它是一种有争议的美容程序,其疗效仍缺乏证据。作者在十多年前就曾发表过一篇关于该治疗方法的综述。当时,仅有少数评估其疗效和安全性的临床研究,且没有关于其疗效的明确科学证据;尽管如此,许多非医疗和医疗专业人员仍继续以相对较高的经济成本为患者进行这种治疗,以达到抗衰老的目的。作者在十多年前就曾发表过一篇关于该治疗方法的综述。本次综述是对该方法自那时以来出现的任何科学有效性和疗效证据的更新。没有发现有临床价值的新数据和新信息。根据美国整形外科学会(ASPS)在 2019 年更新并批准的政策声明,目前中胚层疗法并未获得食品和药物管理局的批准用于皮肤年轻化。在获得更明确的数据之前,不能推荐将皮肤年轻化中胚层疗法常规应用于皮肤年轻化的临床实践。